Incannex Company Presentation – Presentation of Psychennex, Psychedelic Therapies Subsidiary Company

Rhea-AI Summary

Incannex Healthcare Ltd announces a company presentation on its psychedelic therapies subsidiary company, Psychennex.

MELBOURNE, Australia, May 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation which details activities of its psychedelic therapies subsidiary company, called Psychennex.

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

Incannex Contact Information:

Incannex Healthcare Limited
Mr Joel Latham
Managing Director and Chief Executive Officer
+61 409 840 786
joel@incannex.com.au

Investor Relations Contact – United States
Alyssa Factor
Edison Group
+1 (860) 573 9637
afactor@edisongroup.com

FAQ

What is the name of Incannex Healthcare Ltd's psychedelic therapies subsidiary company?

The name of the subsidiary company is Psychennex.

Who is the Managing Director and Chief Executive Officer of Incannex Healthcare Limited?

The Managing Director and Chief Executive Officer of Incannex Healthcare Limited is Mr. Joel Latham.

What is the contact information for Incannex Healthcare Limited?

The contact information for Incannex Healthcare Limited is as follows: Mr. Joel Latham, Managing Director and Chief Executive Officer, can be reached at +61 409 840 786 or joel@incannex.com.au. For investor relations in the United States, Alyssa Factor from Edison Group can be contacted at +1 (860) 573 9637 or afactor@edisongroup.com.